Ultrasensitive digital immunoassays for SOD1 conformation in amyotrophic lateral sclerosis.
Lisa MorichonChristophe HirtzLaurent TiersAlexandre MezghraniCédric RaoulFlorence EsselinElisa De La CruzJean-Pierre JulienWilliam CamuSylvain LehmannPublished in: Bioanalysis (2023)
Aim: The aim of this study was to detect misfolded Cu/Zn SOD1 as a potential biomarker for amyotrophic lateral sclerosis (ALS). Materials & methods: Two ultrasensitive immunodetection assays were developed for the quantification of total and misfolded SOD1. Results: The detection of total and misfolded SOD1 was possible in human serum and cerebrospinal fluid. Total SOD1 was increased in cerebrospinal fluid from ALS patients. Misfolded SOD1 had low and variable expression in both control and ALS patient samples. Conclusion: These assays hold promise for improving our understanding of ALS and its detection, and could lead to more effective treatment options in the future. Further studies in larger cohorts are now required.
Keyphrases
- amyotrophic lateral sclerosis
- cerebrospinal fluid
- label free
- end stage renal disease
- gold nanoparticles
- chronic kidney disease
- high throughput
- poor prognosis
- newly diagnosed
- loop mediated isothermal amplification
- peritoneal dialysis
- real time pcr
- current status
- machine learning
- molecular dynamics simulations
- high resolution
- patient reported
- deep learning
- artificial intelligence
- case control
- sensitive detection
- metal organic framework